Phillip Neri Aguilar, NP
Nurse Practitioner · Long Beach
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 6 years
- Graduated 2020
Offices
1 location · Advances in Mental Health and Addictions Treatment Inc · 6 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Phillip Neri Aguilar’s office at (562) 365-2020 to ask if they take your plan before you enroll.
Medicaid work
$51,397 in 2024
Medicaid paid $51,397 for 839 billed services this clinician did in 2024, up to 55 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 300 | $51,031 |
| Short return visit | 96 | $198 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 443 | $168 |
| 2024 | 839 | 3 | 55 | $51,397 |
| 2023 | 216 | 1 | 27 | $0 |
See the largest Medicaid services in earlier years
2023
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 216 | $0 |
Drugs they prescribed that Part D paid
$19,793
Pharmacies billed $19,793 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,136) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,135 generic and fewer than 11 brand-name prescriptions · $19,793 in drug cost · 88 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ziprasidone | 24 | $1,156 | $48 |
| Olanzapine | 101 | $1,149 | $11 |
| Quetiapine | 91 | $1,079 | $12 |
| Olanzapine Odt | 11 | $844 | $77 |
| Aripiprazole | 43 | $730 | $17 |
See all 25 drugs
| Ziprasidone | 24 | $1,156 | $48 |
| Olanzapine | 101 | $1,149 | $11 |
| Quetiapine | 91 | $1,079 | $12 |
| Olanzapine Odt | 11 | $844 | $77 |
| Aripiprazole | 43 | $730 | $17 |
| Risperidone | 66 | $710 | $11 |
| Lurasidone | 13 | $680 | $52 |
| Buspirone | 38 | $672 | $18 |
| Divalproex | 33 | $668 | $20 |
| Trazodone | 113 | $640 | $6 |
| Benztropine Mesylate | 63 | $480 | $8 |
| Hydroxyzine | 34 | $372 | $11 |
| Fluoxetine | 50 | $345 | $7 |
| Carbamazepine | 22 | $322 | $15 |
| Sertraline | 89 | $319 | $4 |
| Bupropion Xl | 14 | $273 | $20 |
| Escitalopram | 43 | $231 | $5 |
| Mirtazapine | 13 | $180 | $14 |
| Gabapentin | 35 | $149 | $4 |
| Fluphenazine | 11 | $137 | $12 |
| Clonazepam | 33 | $111 | $3 |
| Hydroxyzine Pamoate | 28 | $103 | $4 |
| Paroxetine | 28 | $93 | $3 |
| Donepezil | 15 | $80 | $5 |
| Lorazepam | 21 | $43 | $2 |
Year by year
| 2024 | 1,136 | 77 | 0% (0) | None | $19,793 |
| 2023 | 601 | 68 | 0% (0) | None | $10,530 |
| 2022 | 19 | None | 0% (0) | 0% | $1,104 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Olanzapine Odt | 11 | $2,035 | $185 |
| Quetiapine | 60 | $1,087 | $18 |
| Trazodone | 97 | $799 | $8 |
| Aripiprazole | 32 | $584 | $18 |
| Hydroxyzine | 42 | $561 | $13 |
| Olanzapine | 36 | $540 | $15 |
| Buspirone | 29 | $363 | $13 |
| Risperidone | 19 | $340 | $18 |
| Paroxetine | 38 | $297 | $8 |
| Fluoxetine | 31 | $280 | $9 |
| Gabapentin | 24 | $259 | $11 |
| Sertraline | 46 | $248 | $5 |
| Dextroamphetamine-Amphetamine | 19 | $213 | $11 |
| Escitalopram | 15 | $138 | $9 |
| Clonazepam | 14 | $133 | $9 |
Money from drug and device companies
$846 in 2025
| 2025 | 7 | 28 | None | $846 |
| 2024 | 6 | 36 | None | $982 |
| 2023 | 6 | 42 | None | $1,186 |
| 2022 | 4 | 12 | None | $299 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $418 | 8 payments
|
| Abbvie | Vraylar | $183 | 12 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $103 | 3 payments
|
| Vanda Pharmaceuticals | Fanapt | $61 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $30 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $28 | 1 payment
|
See all 28 published payments
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-09 | Caplyta | $129 |
| Vanda Pharmaceuticals | Meals · 2025-11-13 | Fanapt | $26 |
| Abbvie | Meals · 2025-10-24 | Vraylar | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-17 | Caplyta | $33 |
| Janssen Pharmaceuticals | Meals · 2025-10-08 | Invega Sustenna | $35 |
| Abbvie | Meals · 2025-10-03 | Vraylar | $7 |
| Collegium Pharmaceutical | Meals · 2025-10-02 | Jornay Pm | $23 |
| Abbvie | Meals · 2025-09-22 | Vraylar | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-19 | Cobenfy | $30 |
| Janssen Pharmaceuticals | Meals · 2025-09-12 | Invega Sustenna | $32 |
| Vanda Pharmaceuticals | Meals · 2025-08-08 | Fanapt | $36 |
| Janssen Pharmaceuticals | Meals · 2025-08-01 | Invega Sustenna | $36 |
| Abbvie | Meals · 2025-07-25 | Vraylar | $5 |
| Abbvie | Meals · 2025-07-18 | Vraylar | $20 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-26 | Caplyta | $27 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-13 | Caplyta | $27 |
| Abbvie | Meals · 2025-06-12 | Vraylar | $8 |
| Abbvie | Meals · 2025-06-12 | Vraylar | $5 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-23 | Caplyta | $27 |
| Abbvie | Meals · 2025-05-16 | Vraylar | $24 |
| Abbvie | Meals · 2025-03-27 | Vraylar | $19 |
| Abbvie | Meals · 2025-03-06 | Vraylar | $25 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-27 | Caplyta | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-12 | Caplyta | $148 |
| Otsuka America Pharmaceutical | Meals · 2025-01-30 | Rexulti | $28 |
| Abbvie | Meals · 2025-01-24 | Vraylar | $8 |
| Abbvie | Meals · 2025-01-24 | Vraylar | $31 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-01-24 | Caplyta | $8 |
See earlier years (2024, 2023, 2022)
2024: $982
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $282 | 10 payments
|
| Alkermes | Aristada | $242 | 7 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $235 | 6 payments
|
| Abbvie | Vraylar | $169 | 11 payments
|
| Hologic Sales and Service | Aptima | $30 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $24 | 1 payment
|
2023: $1,186
| Janssen Pharmaceuticals | Invega Sustenna | $512 | 18 payments
|
| Iti | Caplyta | $231 | 10 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $231 | 6 payments
|
| Alkermes | Aristada | $171 | 6 payments
|
| AbbVie | Vraylar | $21 | 1 payment
|
| Ironshore Pharmaceuticals | Jornay Pm | $20 | 1 payment
|
2022: $299
| Janssen Pharmaceuticals | Invega Sustenna | $156 | 6 payments
|
| Iti | Caplyta | $61 | 2 payments
|
| Alkermes | Aristada | $60 | 3 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $22 | 1 payment
|
Professional record
- NPI
- 1043942477
- Licence
- CA 95021440
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 6010 Briercrest Ave, Lakewood, CA, 90713
- NPI first listed
- 2022-06-24
- NPI last updated
- 2022-06-24
- NPI record certified
- 2022-06-24
This is when the NPI record was last certified, not a medical board exam.